Atlanta

This first-of-its-kind scientific conference will bring under one roof leading breast cancer researchers, clinicians, epidemiologists, students, and patients from around the world to examine risk factors for TNBC from diverse domains of influence at multiple levels and to discuss clinical management strategies that can deliver the promise of precision treatments for TNBC patients. Your valued participation is a testament to your commitment to join hands and improve outcomes for TNBC patients.

Sincerely,

RITU ANEJA, PhD

Conference Chair

EMAD A. RAKHA, MD, PhD, FRCPath

Conference Co-Chair

MYLIN A. TORRES, MD

Conference Co-Chair



The 2017 International TNBC Conference is made possible by grants from the National Institute of Minority Health and Health Disparities, Pfizer, Inc.

and Georgia State University

We are deeply grateful to our partners for their sponsorship and support of this event


































CONFERENCE AGENDA

September 18-20, 2017

Georgia State University Atlanta, GA, USA TNBCconference.org





MONDAY, SEPTEMBER 18

Centennial Hall, 100 Auburn Avenue, Atlanta, GA 30303

REGISTRATION & BREAKFAST

INAUGURAL SESSION

Session Chair - Ritu Aneja, PhD

- 8:30 Welcome Remarks James Weyhenmeyer, PhD, Vice President for Research and Economic Development, Georgia State University, USA
- 8:45 Inaugural Address Ian O. Ellis, MD, FRCPath University of Nottingham, UK, Triple Negative Breast Cancer: A Pathologist's Perspective
- Keynote Talk Charles M. Perou, MD, University of North Carolina - Chapel Hill, USA, Triple Negative Breast Cancer: Biology and Heterogeneity
- 9:45 Latoya Johnson, TNBC Survivor

10:00 COFFEE BREAK

SESSION I: Predictive & Prognostic Biomarkers

Session Chair - Ian O. Ellis, FRCPath

- 10:45 Maria Foschini, MD University of Bologna, Italy, Morphological and Molecular Features of TNBC
- Christos Hatzis, PhD Yale Cancer Center, USA, Genomic Heterogeneity of Triple Negative Breast Cancer and its **Effect on Patient Selection**
- 11:45 Brian D. Lehmann, PhD Vanderbilt University, USA, Molecular Heterogeneity of Triple Negative Breast Cancer

12:15 LUNCH

SESSION 2: The Biology of TNBC

Session Chair - Vimla Band, PhD

- 1:30 Zsuzsanna Varga, MD University of Zurich, Switzerland, Tumor Microenvironment and TNBC Prognosis
- Grace Callagy, MD, PhD National University of Ireland - Galway, Ireland, Exploring Outcomes for Triple Negative Breast Cancer in an Irish Cohort
- Emiel A. lanssen, PhD University of Stavanger. Norway, MicroRNAs as Biomarkers for TNBC
- COFFEE BREAK

SESSION 3: Novel Therapeutic Targets & Treatments

Session Chair - Amelia Zelnack, MD, MSc

- 3:15 Tiffany A. Traina, MD Memorial Sloan Kettering Cancer Center, USA, Targeting the Androgen Receptor in TNBC
- Ruth O'Regan, MD University of Wisconsin Madison, USA, Emerging Targeted Therapies for Metastatic TNBC
- Antonio C. Wolff, MD Johns Hopkins University, USA, Clinical Trial Strategies for Early Stage TNBC
- POSTER PRESENTATIONS

DINNER FOR ALL ATTENDEES

TUESDAY. SEPTEMBER 19

Centennial Hall, 100 Auburn Avenue, Atlanta, GA 30303

REGISTRATION & BREAKFAST

SESSION 4: Breast Cancer-Related Disparities

Session Chair - Jamboor K. Vishwanatha, PhD

- Keynote Talk: Otis Brawley, MD Chief Medical & Scientific Officer, Executive VP of the American Cancer Society, Pertinent Questions Concerning the Disparities in Triple Negative Breast Cancer
- Distinguished Talk: Valerie Montgomery Rice, MD -Morehouse School of Medicine, USA, Addressing Health Disparities in the 21st Century: The Challenge to Achieving Health Equity
- 10:00 Iulie Palmer, ScD Boston University, USA, Contribution of Modifiable Risk Factors to Racial Disparities in TNBC

10:30 COFFEE BREAK

SESSION 5: Precision Medicine, Treatment Strategies & Immunotherapy

Session Chair - Mylin A. Torres, MD

- 11:00 Rita Nanda, MD University of Chicago, USA, Immunotherapy for Triple Negative Breast Cancer: Rationale, Results, and Ongoing Trials
- Periasamy Selvaraj, PhD Emory University, USA, Designing Vaccine Immunotherapy for Heterogeneous Triple Negative Breast Cancer
- 12:00 Hannah Wen MD, PhD Memorial Sloan Kettering Cancer Center, USA, TNBC: Histologic Subtypes and Genetic Alterations

12:30 LUNCH

SESSION 6: Epidemiology, Community- & Practice-Based Studies

Session Chair - Timothy L. Lash. DSc. MPH

- 1:45 Christine Ambrosone, PhD Roswell Park Cancer Institute, USA, Following Molecular Pathways to Understand Risk Factors for ERand Triple Negative Breast Cancer in African-American Women
- 2:15 Ann M. Geiger, PhD, MPH National Cancer Institute, USA, Healthcare Access and Delivery Issues as Contributors to TNBC Disparities
- Theresa Gillespie, PhD, MA, BSN Emory University, USA, Myths and Misperceptions in Breast Cancer Disparities
- **CONCLUDING REMARKS & ANNOUNCEMENT** OF POSTER WINNERS
- 4:00 ICART Vision and Mission (Attendance by invitation only) Emad Rakha, MD, PhD, FRCPath and Ritu Aneja, PhD **ICART Brainstorming Session on Current Provocative** 4:10 Questions Related to TNBC (Attendance by invitation only) Moderated by Emad Rakha, MD, PhD, FRCPath, Emiel A. Janssen, PhD, and Ritu Aneja, PhD

DINNER FOR ICART MEMBERS (Attendance by invitation only)

WEDNESDAY, SEPTEMBER 20*

College of Arts & Sciences Event Center, 25 Park Place NE, Atlanta, GA 30303

* ATTENDANCE BY INVITATION ONLY

8:30 BREAKFAST

- Ayodeji Agboola, MSChB, PhD Overview of African Partnerships with Other ICART Groups Around the World
- 10:00 Adetola Daramola, MBBS, FMCP TNBC: The Lagos University Teaching Hospital Experience
- 10:30 Angela Ogden, PhD Identifying Actionable Biology in TNBC Through Immunohistochemistry-Based Biomarkers
- 11:00 Tanuja Shet, MD Breast Cancer in India: A Pathology Perspective

11:20 COFFEE BREAK

- 11:40 Nikita Wright Comparative Analysis of TNBC Phenotypes and Management in Nigeria, US, UK, and Other Countries
- 12:00 Sergey Klimov Predicting DCIS Recurrence Risk Using High-Content Image Analysis and Machine Learning
- 12:30 Karuna Mittal Centrosome Amplification: A Quantifiable Cancer Cell Trait with Putative Risk Predictive Value in Cancer
- 12:50 Shristi Bhattarai Prognostic Role of Androgen Receptor Expression in TNBC: A Multi Institutional Experience
- Rajeev Soni, PhD Prognostic Value of AR in TNBC: Cohorts, Conundrums and Charting a Course Forward!
- CONCLUDING REMARKS FROM EMAD RAKHA, MD. PhD. FRCPath AND RITU ANEIA, PhD
- LUNCH FOR ICART MEMBER PARTICIPANTS

ORGANIZERS

Ritu Aneja, PhD

Emad A. Rakha, MD, PhD, FRCPath

Mylin A. Torres, MD

Conference Chair

Conference Co-Chair

Conference Co-Chair

SCIENTIFIC COMMITTEE

- Timothy L. Lash, DSc, MPH
- Uma Krishnamurti, MD, PhD
- Lily Yang, MD, PhD
- Emiel A. Janssen, PhD
- Jamboor Vishwanatha, PhD
- Keerthi Gogineni, MD, MSHP - Preeti Subhedar, MD, MSPT
- Monica Rizzo, MD, FACS

- **ORGANIZING COMMITTEE**
- Padmashree C. G. Rida, PhD
- Angela Ogden, PhD - Shailesh Singh, PhD
- Rao Mukkavilli, PhD
- Karuna Mittal, PhD Candidate
- Meenu Mukherji
- Nikki Adams